Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.
“This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer,” said Amit Mahipal, M.D., M.P.H., medical director of Moffitt’s Clinical Research Unit. “Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen.”
ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.
“Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein,” said Mahipal.
Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.
This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.
“New immune therapies are emerging,” explained Mahipal. “If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies.”
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- New prediction model can identify NSCLC patients who are not likely to respond to immunotherapyon August 20, 2021 at 7:45 pm
Immunotherapy agents that inhibit the molecules PD1, PD-L1 or CTLA-4 have become widely used in clinical practice to treat non-small cell lung cancer, or NSCLC.
- PULSAR-integrated radiotherapy with immunotherapy for improved tumor controlon August 20, 2021 at 5:00 pm
Cancer physicians are pioneering a new PULSAR radiation-therapy strategy that improves tumor control compared with traditional daily therapy.
- BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Canceron August 19, 2021 at 12:57 pm
BriaCell to utilize ImaginAb’s CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cellsNEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021 ...
- Immunotherapy Continues to Give Hope for the Future of NSCLC Careon August 19, 2021 at 9:40 am
Nothing in recent years has been more practice changing in the care of non-small cell lung cancer (NSCLC) than the incorporation of immunotherapy. In a recent article in JCO Oncology Practice, Drs.
- Conor Steuer, MD, on Immunotherapy Options for Non-Small Cell Lung Cancer Patientson August 19, 2021 at 7:38 am
Immunotherapy is one of biggest developments in lung cancer treatment, and plays a large role in metastatic lung cancer. Immune checkpoint inhibitors (ICIs) have now become part of the routine care of ...
- Liver Metastases Linked to Immunotherapy Resistance in Microsatellite Stable Colorectal Canceron August 19, 2021 at 6:00 am
Checkpoint inhibitors can be effective against microsatellite stable (MSS) colorectal cancer (CRC), but patients with liver metastases appear resistant to these drugs, according to a retrospective ...
- Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Breast Canceron August 18, 2021 at 8:08 am
The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer ...
- Immunotherapy Market Size Growing at 6.7% CAGR to hit USD 179100 million by 2025on August 17, 2021 at 8:53 am
Unscathed by challenges, the worldwide Immunotherapy market is expected to record a strong CAGR of 6.7% over 2019-2025, consequently multiplying the industry remuneration from USD 106900 million in ...
- Experimental drug and immunotherapy combination shows promise in bladder cancer studyon August 16, 2021 at 5:10 pm
A new study in mice found that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission.
- Experimental drug that boosts immunotherapy shows promise in bladder cancer studyon August 16, 2021 at 10:45 am
A new study in mice found that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission. This approach shows such promise that it's already ...
via Bing News